King rep here. A few points for Pfizer folks to consider:
1. Flector won't break sales records, but it has a place and is easy to sell. Add another 1000 reps selling it, and this can be a $500 million drug. Not alot of money, but not pennies either. The competition for Flector isn't orals, its V-Gel and Lidoderm. Again, if you know how to sell, it can be done.
2. Embeda is hamstrung by compliance wonks. Morphine has a place, and this technology will have a market, if you paint the picture. With M/C coverage getting better, we can make this the 1st line morphine....just need to get it on Hospital formularies. Plus, this technology can be used for other molecules.
3. Remoxy can be a GREAT drug, if we don't get held up by FDA and/or Purdue lawyers. again, tamper-resistant technology, like Embeda, is the future in pain meds.
4. Acurox. Not having the niacin component sucks, but we can still get some business if approved. Short acting...combined with Remoxy/Embeda on the Long-acting side, equals THE pain specialty company.
5. sales force. Seems like there are as many people that want to keep their jobs as there are those that want the severance. Pfizer would do well, in my opinion, to keep the 'performers' on the Long-acting side in place...in key markets. a monkey can sell Flector, but selling opioids is something different.
I hope the waiting game is over soon, and we know our fate. good luck to all.
Regards,
A King rep that wants to keep his job.
